Quest Diagnostics (DGX) EBIAT (2016 - 2025)
Historic EBIAT for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $259.0 million.
- Quest Diagnostics' EBIAT rose 928.27% to $259.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 1528.09%. This contributed to the annual value of $921.0 million for FY2024, which is 143.17% up from last year.
- Latest data reveals that Quest Diagnostics reported EBIAT of $259.0 million as of Q3 2025, which was up 928.27% from $296.0 million recorded in Q2 2025.
- Quest Diagnostics' EBIAT's 5-year high stood at $650.0 million during Q2 2021, with a 5-year trough of $116.0 million in Q4 2022.
- Its 5-year average for EBIAT is $300.7 million, with a median of $249.0 million in 2023.
- As far as peak fluctuations go, Quest Diagnostics' EBIAT soared by 36226.42% in 2021, and later tumbled by 7191.28% in 2022.
- Over the past 5 years, Quest Diagnostics' EBIAT (Quarter) stood at $413.0 million in 2021, then crashed by 71.91% to $116.0 million in 2022, then skyrocketed by 76.72% to $205.0 million in 2023, then grew by 15.12% to $236.0 million in 2024, then grew by 9.75% to $259.0 million in 2025.
- Its EBIAT stands at $259.0 million for Q3 2025, versus $296.0 million for Q2 2025 and $235.0 million for Q1 2025.